gvs 111 has been researched along with Disease Models, Animal in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Gudascheva, TA; Ivanova, EA; Kapitsa, IG; Ostrovskaya, RU; Ozerova, IV; Seredenin, SB; Voronina, TA | 1 |
| Gudasheva, TA; Kuzmina, USh; Ostrovskaya, RU; Salimgareeva, MKh; Seredenin, SB; Vakhitov, VA; Vakhitova, YV; Zainullina, LF | 1 |
| Belnik, AP; Ostrovskaya, RU; Storozheva, ZI | 1 |
| Seredenin, SB | 1 |
| Bobkova, NA; Gruden, MA; Gudasheva, TA; Morozova-Roche, LA; Noppe, W; Ostrovskaya, RU; Samokhin, AN; Seredinin, SB; Sewell, RD; Sherstnev, VV | 1 |
6 other study(ies) available for gvs 111 and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Proline; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles | 2014 |
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cell Survival; Dipeptides; Disease Models, Animal; Humans; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Phosphorylation; Rats; tau Proteins | 2014 |
Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Basal Nucleus of Meynert; Dipeptides; Disease Models, Animal; Humans; Male; Memory Disorders; Nootropic Agents; Peptide Fragments; Random Allocation; Rats; Rats, Wistar | 2008 |
[Pharmacological regulation of emotional stress reactions].
Topics: Adult; Animals; Anti-Anxiety Agents; Benzimidazoles; Benzodiazepines; Dipeptides; Disease Models, Animal; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Morpholines; Personality; Rats; Rats, Inbred Strains; Stress, Psychological; Tranquilizing Agents | 2003 |
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autoantibodies; Behavior, Animal; Dipeptides; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Male; Memory; Mice; Microscopy, Atomic Force; Muramidase; Nerve Growth Factors; Neuroprotective Agents; Nootropic Agents; Olfactory Bulb; Peptide Fragments; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Space Perception; Time Factors | 2007 |